Royal Philips has today announced the expansion of its strategic partnership with Sim&Cure—a partnership that started five years ago and is now entering into its next phase with the aim of further enhancing Philips’ position in the neurointerventional domain by integrating Sim&Size software into Philips’ next-generation image-guided therapy platform, Azurion.
This advanced connection offers care providers a more seamless, intuitive and efficient workflow for treating complex brain aneurysms, according to a Philips press release.
In addition, the two companies will be developing new synergies through common projects to drive innovation into the future of cath labs.
The release notes that current planning and device selection methods in brain aneurysm care involve multiple manual steps, increasing both procedure time and variability. But, by integrating Sim&Size into Azurion, physicians can now simulate device placement, optimise selection and guide deployment directly within the Azurion platform, eliminating the need for separate software and hardware setups, and enabling greater precision and efficiency in neurovascular procedures.
“The strengthened collaboration with Sim&Cure allows us to bring the power of simulation and image-guided therapy together in one platform, enhancing physician confidence and improving patient outcomes,” said Nicole Hermkens, vice president of marketing for Image-Guided Therapy (IGT) Systems at Philips. “By integrating Sim&Size into our Azurion platform, we are reducing complexity and variability in neurovascular procedures, ultimately helping to address the growing burden of brain aneurysms.”
“We are excited to deepen our relationship with Philips and expand our joint impact in neurovascular therapy,” added Mathieu Sanchez, chief executive officer (CEO) of Sim&Cure. “Our combined offering allows clinicians to confidently plan and execute minimally invasive treatments, bringing the best of both companies’ innovations to bear for improved patient care.”
Philips claims that, since its launch in 2017, Azurion has been used to treat more than five million patients in over 90 countries. Earlier this year, the company introduced the latest version of Azurion—a biplane model designed specifically to support neurointerventions that features enhanced 2D and 3D imaging capabilities, improved C-arm rotation flexibility, and optimised workflow features to help clinicians perform complex neurovascular procedures more effectively and efficiently.
